<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41024135</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2056-9920</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>International journal of retina and vitreous</Title><ISOAbbreviation>Int J Retina Vitreous</ISOAbbreviation></Journal><ArticleTitle>Efdamrofusp alfa: an insight into the novel drug and its use in age-related macular degeneration.</ArticleTitle><Pagination><StartPage>100</StartPage><MedlinePgn>100</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40942-025-00685-2</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in older adults, with its prevalence rising globally. This review aims to explore the potential of Efdamrofusp alfa (EA), a novel bispecific decoy receptor fusion protein targeting both VEGF and complement pathways, in treating neovascular AMD (nAMD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A comprehensive literature search was conducted across PubMed, Cochrane and Embase till March 2025 to find articles evaluating the efficacy of EA in the treatment of neovascular AMD. Observations from early pre-clinical studies and clinical trials were analyzed to determine the efficacy and safety of EA.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of five preclinical and clinical studies were included, encompassing 66 animal subjects and 880 human participants. Efdamrofusp alfa (IBI302) neutralizes both C3b/C4b and VEGF, demonstrating anti-angiogenic effects in preclinical models. Clinical trials examined intravitreal doses ranging from 0.05&#xa0;mg to 4.00&#xa0;mg. EA showed efficacy in reducing central retinal thickness and improving visual acuity, with a safety profile comparable to existing anti-VEGF treatments. Treatment-emergent adverse events (TEAEs) included conjunctival hemorrhage, ocular hypertension, and keratitis, which were similar to those observed with other intravitreal anti-VEGF drugs. The drug demonstrated noninferiority to aflibercept in improving best-corrected visual acuity (BCVA) and significantly reduced central subfield thickness.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Efdamrofusp alfa shows promise as a novel treatment for nAMD, potentially offering improved efficacy over current anti-VEGF therapies. Nonetheless, further large-scale randomized clinical trials are essential to confirm its efficacy and safety in broader populations. The dual-inhibition strategy provides a new avenue for personalized AMD treatment, particularly for patients unresponsive to monotherapies.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rath</LastName><ForeName>Shree</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0000-4273-0827</Identifier><AffiliationInfo><Affiliation>All India Institute of Medical Sciences, Bhubaneswar, India. shreerath4a@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibrahim</LastName><ForeName>Arwa Amer</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>University of Sharjah, Sharjah, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Arashdeep</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Government Medical College, Amritsar, Punjab, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Arghadip</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nilratan Sircar Medical College and Hospital, Kolkata, West Bengal, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sediqi</LastName><ForeName>Sayed Mansoor</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>American University of Afghanistan, Kabul, Afghanistan. Dr.mansoorsediqi@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Najia Ali</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Khyber Medical College, Peshawar, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panchal</LastName><ForeName>Krisha</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Smt. NHL Municipal Medical College, Ahmedabad, Gujarat, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mian</LastName><ForeName>Safwan Masaud</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Khyber Medical College, Peshawar, Pakistan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Retina Vitreous</MedlineTA><NlmUniqueID>101677897</NlmUniqueID><ISSNLinking>2056-9920</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Age-related macular degeneration (AMD)</Keyword><Keyword MajorTopicYN="N">Bispecific protein</Keyword><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">Efdamrofusp alfa</Keyword><Keyword MajorTopicYN="N">Immunotherapy</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41024135</ArticleId><ArticleId IdType="doi">10.1186/s40942-025-00685-2</ArticleId><ArticleId IdType="pii">10.1186/s40942-025-00685-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102(11):1640&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archopht.1984.01040031330019</ArticleId><ArticleId IdType="pubmed">6208888</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores R, Carneiro &#xc2;, Vieira M, Tenreiro S, Seabra MC. Age-related macular degeneration: pathophysiology, management, and future perspectives. Ophthalmologica. 2021;244(6):495&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000517520</ArticleId><ArticleId IdType="pubmed">34130290</ArticleId></ArticleIdList></Reference><Reference><Citation>Gheorghe A, Mahdi L, Musat O. Age-related macular degeneration. Roman J Ophthalmol. 2015;59(2):74&#x2013;7.</Citation></Reference><Reference><Citation>Abdelsalam A, Del Priore L, Zarbin MA. Drusen in age-related macular degeneration. Surv Ophthalmol. 1999;44(1):1&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0039-6257(99)00072-7</ArticleId><ArticleId IdType="pubmed">10466585</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashshur ZF, Schakal A, Hamam RN, Haibi CPE, Jaafar RF, Noureddin BN. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol. 2007;125(10):1357&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archopht.125.10.1357</ArticleId><ArticleId IdType="pubmed">17923543</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JW. Comparison of age-related macular degeneration treatments trials 2: introducing comparative effectiveness research. Ophthalmology. 2020;127(4):S133&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2019.11.025</ArticleId><ArticleId IdType="pubmed">32200812</ArticleId></ArticleIdList></Reference><Reference><Citation>Guymer RH, Wu Z, Hodgson LAB, Caruso E, Brassington KH, Tindill N, et al. Subthreshold nanosecond laser intervention in age-related macular degeneration. Ophthalmology. 2019;126(6):829&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2018.09.015</ArticleId><ArticleId IdType="pubmed">30244144</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladas ID, Chatziralli IP, Kotsolis AI, Douvali M, Georgalas I, Theodossiadis PG, et al. Intravitreal ranibizumab versus thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularization secondary to age-related macular degeneration. Ophthalmologica. 2012;228(2):93&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000337347</ArticleId><ArticleId IdType="pubmed">22571933</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren X, Li J, Xu X, Wang C, Cheng Y. IBI302, a promising candidate for AMD treatment, targeting both the VEGF and complement system with high binding affinity in vitro and effective targeting of the ocular tissue in healthy rhesus monkeys. Exp Eye Res. 2016;145:352&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2016.02.004</ArticleId><ArticleId IdType="pubmed">26919788</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Li T, Jia H, Gao M, Li Y, Wan X, et al. Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy. Sci Transl Med. 2022;14(647):eabj2177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abj2177</ArticleId><ArticleId IdType="pubmed">35648811</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis. Genes Cancer. 2011;2(12):1097&#x2013;105. https://doi.org/10.1177/1947601911423031 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1947601911423031</ArticleId><ArticleId IdType="pubmed">22866201</ArticleId><ArticleId IdType="pmc">3411125</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya M. Role of vegf-flt receptor system in normal and tumor angiogenesis. In: Vande Woude GF, Klein G, editors. Advances in cancer research, vol. 67. Academic Press; 1995. p. 281&#x2013;316.</Citation></Reference><Reference><Citation>Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol Baltim Md 1950. 2013;190(8):3831&#x2013;8. https://doi.org/10.4049/jimmunol.1203487 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1203487</ArticleId></ArticleIdList></Reference><Reference><Citation>Markiewski MM, Daugherity E, Reese B, Karbowniczek M. The role of complement in angiogenesis. Antibodies. 2020;9(4):67. https://doi.org/10.3390/antib9040067 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib9040067</ArticleId><ArticleId IdType="pubmed">33271774</ArticleId><ArticleId IdType="pmc">7709120</ArticleId></ArticleIdList></Reference><Reference><Citation>Nozaki M, Raisler BJ, Sakurai E, et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A. 2006;103(7):2328&#x2013;33. https://doi.org/10.1073/pnas.0408835103 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0408835103</ArticleId><ArticleId IdType="pubmed">16452172</ArticleId><ArticleId IdType="pmc">1413680</ArticleId></ArticleIdList></Reference><Reference><Citation>Bressler SB, Maguire MG, Bressler NM, Fine SL. Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group. Arch Ophthalmol Chic Ill 1960. 1990;108(10):1442&#x2013;7. https://doi.org/10.1001/archopht.1990.01070120090035 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archopht.1990.01070120090035</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385&#x2013;9. https://doi.org/10.1126/science.1109557 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1109557</ArticleId><ArticleId IdType="pubmed">15761122</ArticleId><ArticleId IdType="pmc">1512523</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweigard JH, Yanai R, Gaissert P, et al. The alternative complement pathway regulates pathological angiogenesis in the retina. FASEB J. 2014;28(7):3171&#x2013;82. https://doi.org/10.1096/fj.14-251041 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.14-251041</ArticleId><ArticleId IdType="pubmed">24668752</ArticleId><ArticleId IdType="pmc">4062823</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia H, Li T, Sun J, et al. A novel bispecific fusion protein targeting C3b/C4b and VEGF in patients With nAMD: a randomized, open-label, Phase 1b study. Am J Ophthalmol. 2023;248:8&#x2013;15. https://doi.org/10.1016/j.ajo.2022.11.016 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2022.11.016</ArticleId><ArticleId IdType="pubmed">36410472</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Song Y, Gong Y, et al. Efficacy and safety of efdamrofusp alfa versus aflibercept in participants with neovascular age-related macular degeneration: a randomized, double-masked, active-controlled, non-inferiority, phase 2 trial. Ophthalmol Retina. 2024. https://doi.org/10.1016/j.oret.2024.08.014 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2024.08.014</ArticleId><ArticleId IdType="pubmed">39577561</ArticleId></ArticleIdList></Reference><Reference><Citation>A Phase 3, Randomized, Double-masked, Active-Controlled Study to Evaluate the Efficacy and Safety of Intravitreal IBI302(Efdamrofusp Alfa) in Subjects With Neovascular Age-Related Macular Degeneration. Published online July 25, 2023. Accessed August 15, 2023. https://clinicaltrials.gov/study/NCT05972473 .</Citation></Reference><Reference><Citation>Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration [published correction appears in Ophthalmology. Ophthalmology. 2012;119(12):2537&#x2013;48. https://doi.org/10.1016/j.ophtha.2012.09.006 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2012.09.006</ArticleId><ArticleId IdType="pubmed">23084240</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta H, Tufail A, Daien V, et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res. 2018;65:127&#x2013;46. https://doi.org/10.1016/j.preteyeres.2017.12.002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2017.12.002</ArticleId><ArticleId IdType="pubmed">29305324</ArticleId></ArticleIdList></Reference><Reference><Citation>CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897&#x2013;908. https://doi.org/10.1056/NEJMoa1102673 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1102673</ArticleId></ArticleIdList></Reference><Reference><Citation>Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maguire MG, Martin DF, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(8):1751&#x2013;61. https://doi.org/10.1016/j.ophtha.2016.03.045 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2016.03.045</ArticleId></ArticleIdList></Reference><Reference><Citation>Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292&#x2013;9. https://doi.org/10.1016/j.ophtha.2013.03.046 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2013.03.046</ArticleId><ArticleId IdType="pubmed">23642856</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 Eyes. Ophthalmol Retina. 2020;4(1):19&#x2013;30. https://doi.org/10.1016/j.oret.2019.05.017 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2019.05.017</ArticleId><ArticleId IdType="pubmed">31324588</ArticleId></ArticleIdList></Reference><Reference><Citation>Mettu PS, Allingham MJ, Cousins SW. Incomplete response to Anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res. 2021;82: 100906. https://doi.org/10.1016/j.preteyeres.2020.100906 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2020.100906</ArticleId><ArticleId IdType="pubmed">33022379</ArticleId></ArticleIdList></Reference><Reference><Citation>Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015;49:67&#x2013;81. https://doi.org/10.1016/j.preteyeres.2015.06.002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2015.06.002</ArticleId><ArticleId IdType="pubmed">26113211</ArticleId><ArticleId IdType="pmc">4651818</ArticleId></ArticleIdList></Reference><Reference><Citation>Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013;27:787&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/eye.2013.107</ArticleId><ArticleId IdType="pubmed">23722722</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond). 2009;23(1):181&#x2013;5. https://doi.org/10.1038/sj.eye.6702938 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.eye.6702938</ArticleId><ArticleId IdType="pubmed">17693999</ArticleId></ArticleIdList></Reference><Reference><Citation>Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma. 2009;18(9):658&#x2013;61. https://doi.org/10.1097/IJG.0b013e31819c4893 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IJG.0b013e31819c4893</ArticleId><ArticleId IdType="pubmed">20010243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahook MY, Kimura AE, Wong LJ, Ammar DA, Maycotte MA, Mandava N. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging. 2009;40(3):293&#x2013;5. https://doi.org/10.3928/15428877-20090430-12 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/15428877-20090430-12</ArticleId><ArticleId IdType="pubmed">19485295</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang QV, Mendonca LS, Della Torre KE, Jung JJ, Tsuang AJ, Freund KB. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology. 2012;119(2):321&#x2013;6. https://doi.org/10.1016/j.ophtha.2011.08.011 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2011.08.011</ArticleId><ArticleId IdType="pubmed">22054994</ArticleId></ArticleIdList></Reference><Reference><Citation>Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011;95(8):1111&#x2013;4. https://doi.org/10.1136/bjo.2010.180729 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjo.2010.180729</ArticleId><ArticleId IdType="pubmed">20702430</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezad-Koursh D, Goldstein M, Heilwail G, Zayit-Soudry S, Loewenstein A, Barak A. Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor. Retina. 2010;30(7):1051&#x2013;7. https://doi.org/10.1097/IAE.0b013e3181cd47ed .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0b013e3181cd47ed</ArticleId><ArticleId IdType="pubmed">20616683</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah CP, Garg SJ, Vander JF, et al. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology. 2011;118(10):2028&#x2013;34. https://doi.org/10.1016/j.ophtha.2011.02.034 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2011.02.034</ArticleId><ArticleId IdType="pubmed">21705087</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.prnewswire.com/news-releases/innovent-announces-primary-endpoint-met-in-the-second-phase-2-clinical-trial-of-ibi302-anti-vegfcomplement-in-treating-neovascular-age-related-macular-degeneration-namd-302091578.html cited 15th September,2024</Citation></Reference><Reference><Citation>Juan et al. &#x201c;Limited macular translocation&#x201d; eye2001146</Citation></Reference><Reference><Citation>Panos G, Lakshmanan A, Dadoukis P, Ripa M, Motta L, Amoaku W. Faricimab: transforming the future of macular diseases treatment - a comprehensive review of clinical studies. Drug Des Dev Ther. 2023;17:2861&#x2013;73. https://doi.org/10.2147/dddt.s427416 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/dddt.s427416</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrasekaran PR, Madanagopalan VG. KSI-301: antibody biopolymer conjugate in retinal disorders. Ther Adv Ophthalmol. 2021. https://doi.org/10.1177/25158414211027708 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/25158414211027708</ArticleId><ArticleId IdType="pubmed">34291186</ArticleId><ArticleId IdType="pmc">8278447</ArticleId></ArticleIdList></Reference><Reference><Citation>Campochiaro PA, Avery R, Brown DM, Heier JS, Ho AC, Huddleston SM, et al. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study. The Lancet. 2024;403:1563&#x2013;73. https://doi.org/10.1016/s0140-6736(24)00310-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(24)00310-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson TL, Slakter J, Buyse M, Wang K, Dugel PU, Wykoff CC, et al. A randomized controlled trial of OPT-302, a VEGF-C/D inhibitor for neovascular age-related macular degeneration. Ophthalmology. 2023;130:588&#x2013;97. https://doi.org/10.1016/j.ophtha.2023.02.001 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2023.02.001</ArticleId><ArticleId IdType="pubmed">36754174</ArticleId></ArticleIdList></Reference><Reference><Citation>Anton N, Doroftei B, Curteanu S, Cat&#xe3;lin L, Ilie OD, T&#xe2;rcoveanu F, et al. Comprehensive review on the use of artificial intelligence in ophthalmology and future research directions. Diagnostics (Basel). 2022. https://doi.org/10.3390/diagnostics13010100 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics13010100</ArticleId><ArticleId IdType="pubmed">36611392</ArticleId><ArticleId IdType="pmc">9818832</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachigian LM, Liew G, Teo KYC, Wong TY, Mitchell P. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. J Transl Med. 2023;21(1):133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-023-03937-7</ArticleId><ArticleId IdType="pubmed">36810060</ArticleId><ArticleId IdType="pmc">9942398</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>